Participants 0 173 8
Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type.
Participants 608 732 3
double-blind, randomized, multicenter study comparing patches containing 30 mg and 60 mg physostigmine with a placebo patch.
Participants 737 922 5
clinical trial followed the basic principles of the various guidelines on the evaluation of anti-dementia drugs, and included patients with mild to moderate probable Alzheimer's disease
Participants 924 1009 9
A total of 204 patients with probable Alzheimer's disease were included in the study.
Participants 1010 1215 8
Of these, 136 patients were eligible for the according-to-protocol analysis of efficacy, 167 subjects for the intention-to-treat analysis of efficacy, and 181 patients were included in the safety analysis.
Participants 1456 1491 3
better outcome in the placebo group
